Presentation is loading. Please wait.

Presentation is loading. Please wait.

NSAIDs and esophageal cancer

Similar presentations


Presentation on theme: "NSAIDs and esophageal cancer"— Presentation transcript:

1 NSAIDs and esophageal cancer
Hans Scherübl, Andreas P Sutter, Martin Zeitz  Gastroenterology  Volume 125, Issue 6, Pages (December 2003) DOI: /j.gastro

2 Figure 1 Antiproliferative effects of selenomethionine in ESCC cells. (A) Proliferation of the human ESCC cell line KYSE-140 was evaluated by crystal violet staining after 96 hours of incubation with selenomethionine (1–1000 μmol/L). Measurements were performed as previously described (Sutter et al. Int J Cancer 2002;102:318–327). Selenomethionine induced dose-dependent growth inhibition (IC50 = 62 μmol/L). Data are given as percentage of untreated control. (B) Cell cycle analysis of KYSE-140 cells was performed by propidium iodide staining of isolated nuclei (Vindelov, Christensen. Methods Cell Biol 1990;33:127–137). After 48 hours of incubation with selenomethionine (50–500 μmol/L), KYSE-140 cells accumulated in the G2/M phase (white columns) of the cell cycle but decreased in the S phase (hatched columns) and G0/G1 phase (black columns). These data suggest that selenomethionine-induced growth inhibition in ESCC cells is caused by G2/M arrest. Gastroenterology  , DOI: ( /j.gastro )


Download ppt "NSAIDs and esophageal cancer"

Similar presentations


Ads by Google